Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC

被引：0
|
作者：
Pinto, L. Masfarre [1 ]
Rocha, P. [2 ]
Clave, S. [3 ]
Gorro, N. Navarro [4 ]
Sanchez, I. [3 ]
Giner, M. [5 ]
Lloret, A. Corbera [4 ]
Garcia, A. Taus [4 ]
Parreira, A. S. D. F. M. [6 ]
Paricio, B. Bellosillo [7 ]
Arriola, E. [1 ]
机构：
[1] Hosp Mar Parc Salut Mar, Dept Oncol, Barcelona, Spain
[2] Hosp Mar Parc Salut Mar, Translat Mol Pathol Dept, Barcelona, Spain
[3] Hosp Mar Parc Salut Mar, Dept Pathol, Barcelona, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Mar Parc Salut Mar, Barcelona, Spain
[6] Hosp Univ Son Espases, Med Oncol, Palma De Mallorca, Spain
[7] Hosp Mar Parc Salut Mar, Dept Mol Biol, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
收藏
页码：S145 / S146
页数：2
相关论文
共 50 条
  • [1] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [2] Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
    Pinto, L. Masfarre
    Parreira, A. S. D. F. M.
    Unanua, N. Castro
    Rocha, P.
    Ruiz, I. Morilla
    Sanchez, L. Teijeira
    Clave, S.
    Gorro, N. Navarro
    Mora, R. Bach
    Sanchez, I.
    Campos, M. A. Galindo
    Garcia, A. Taus
    Martinez, A. Azkarate
    Fabregat, R. Marse
    Paricio, B. Bellosillo
    Arasanz, H.
    Aguillo, M. Martinez
    Arriola, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [3] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
  • [4] Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
    Notario, Lucia
    Cucurull, Marc
    Cerda, Gabriela
    Sanz, Carolina
    Carcereny, Enric
    Munoz-Marmol, Ana
    Hernandez, Ainhoa
    Domenech, Marta
    Moran, Teresa
    Sanchez-Cespedes, Montse
    Costa, Marta
    Mate, Jose-Luis
    Esteve, Anna
    Saigi, Maria
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [6] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
    Barot, Hasti
    Evans, Joanne
    Mohammed, Waleed
    Power, Danielle
    LUNG CANCER, 2022, 165 : S77 - S77
  • [7] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [8] Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients
    Jacobs, Francesca
    Cani, Massimiliano
    Malapelle, Umberto
    Novello, Silvia
    Napoli, Valerio Maria
    Bironzo, Paolo
    CANCERS, 2021, 13 (24)
  • [9] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [10] Sotorasib in KRAS p.G12C-mutated NSCLC
    Gassa, Asmae
    Oezkan, Filiz
    Bruns, Christiane
    Schmidt, Thomas
    Alakus, Hakan
    ONKOLOGE, 2021, 27 (10): : 1031 - 1032
12345